News about "clinical development "

MedPharm Becomes First Olink Certified Service Provider in the Carolinas

MedPharm has become an Olink Certified Service Provider, adding multiplex proteomic analysis to its human-relevant research capabilities and becoming the first Olink CSP in the Carolinas.

Clinical Development | 24/08/2026 | By News Bureau

Harbour BioMed Secures China IND Approval for HBM7004 in Advanced Solid Tumours

NMPA clearance advances the B7H4xCD3 bispecific antibody toward clinical development, following promising preclinical efficacy and safety results and recent US FDA clearance.

Clinical Development | 19/08/2026 | By News Bureau

RiboX Wins FDA IND Clearance for First Circular RNA-Based In Vivo CAR-T Therapy

RiboX Therapeutics receives FDA IND clearance for RXIM002, an investigational circRNA-based in vivo CAR-T therapy designed to generate CD19-targeted CAR-T cells directly inside the body for autoimmune cytopenias.

Clinical Development | 10/08/2026 | By News Bureau

Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.

Clinical Development | 27/07/2026 | By News Bureau

Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity

Ascletis Pharma has selected its ASC30-ASC48 fixed-dose combination for clinical development as a once-daily oral therapy for obesity. The dual-target GLP-1R/GIPR candidate demonstrated encouraging preclinical efficacy, with an IND submission to the US FDA planned for Q4 2026.

Clinical Development | 17/07/2026 | By News Bureau |  152

Can-Fite BioPharma Secures Australian Patent for Namodenoson in Advanced Metastatic Cancer

Can-Fite BioPharma has secured an Australian patent covering the use of Namodenoson for advanced metastatic cancer, strengthening intellectual property protection as the drug advances through late-stage clinical development for liver and pancreatic cancers.

Clinical Development | 15/07/2026 | By News Bureau

PharmAla Completes GMP Manufacturing for ALA-002

PharmAla has completed GMP manufacturing of ALA-002 drug substance components and is preparing to begin GMP drug product manufacturing for upcoming global clinical trials.

Clinical Development | 07/07/2026 | By News Bureau

Colorectal Cancer Alliance, GCAR Launch Adaptive KLEOS Trial Platform to Accelerate Colorectal Cancer Treatment Development

The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.

Clinical Development | 01/06/2026 | By News Bureau |  100

Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD

Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.

Clinical Development | 25/03/2026 | By News Bureau |  316

Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity

Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.

Clinical Development | 21/03/2026 | By News Bureau |  351